Cost-Effectiveness of Culmerciclib Plus Fulvestrant for Previously Treated HR-Positive/HER2-Negative Advanced Breast Cancer in China: An Integrated GBD 2023 Analysis
International Journal of Women's Health · 2026-10 · Volume 18 · 1-18
DOI: 10.2147/ijwh.s636398 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Women's Health, 2026-10. Verfasst von Feng Xuan und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, Zhuji Affiliated Hospital of Wenzhou Medical University, Shaoxing, Zhejiang, People's Republic of China. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).
Abstract (Originalsprache)
Background
Breast cancer (BC) imposes a substantial and evolving health and economic burden in China. We integrated population-level disease burden with treatment-specific economic evaluation to assess the cost-effectiveness of culmerciclib plus fulvestrant for previously treated hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC).
Methods
Using Global Burden of Disease Study 2023 data, we assessed BC incidence, prevalence, mortality, disability-adjusted life-years (DALYs), and temporal trends in China. GBD estimates provided population-level context and were not direct inputs into the economic model. We then conducted a lifetime cost-effectiveness analysis from the Chinese healthcare perspective, comparing culmerciclib plus fulvestrant with placebo plus fulvestrant for previously treated HR+/HER2- ABC based on randomized Phase III trial efficacy. Outcomes included costs, life-years, quality-adjusted life-years (QALYs), and incremental cost-effectiveness ratios (ICERs). The willingness-to-pay (WTP) threshold was $26,896/QALY, equivalent to twice China's per-capita gross domestic product.
Results
In 2023, BC caused 342,725 incident cases, 3,496,338 prevalent cases, 76,589 deaths, and 2,458,481 DALYs in China. From 1990 to 2023, the age-standardized rates (ASRs) of incidence and prevalence increased, whereas the ASRs of mortality and DALY decreased. All four ASRs rose during 2020-2023. In the base-case analysis, culmerciclib plus fulvestrant provided an additional 0.90 QALYs at an incremental cost of $34,150.43 compared with placebo plus fulvestrant, resulting in an ICER of $37,886.61/QALY. At the prespecified WTP threshold, the probability of culmerciclib plus fulvestrant being cost-effective was 2.7%. Culmerciclib price was the main uncertainty driver. A 25% reduction in the price of culmerciclib lowered the ICER to $26,677.03/QALY.
Conclusions
Against the background of a substantial and evolving BC burden in China, culmerciclib plus fulvestrant provides additional health benefits but is unlikely to be cost-effective compared with placebo plus fulvestrant for previously treated HR+/HER2- ABC at its current price. Integrating population-level disease burden with treatment-specific economic evidence provides complementary information for healthcare resource allocation.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Radiation Oncology, Zhuji Affiliated Hospital of Wenzhou Medical University, Shaoxing, Zhejiang, People's Republic of China.
- Department of Quality Management, Zhuji Blood Bank, Shaoxing, Zhejiang, People's Republic of China.
- Department of Medical Oncology, Zhuji Affiliated Hospital of Wenzhou Medical University, Shaoxing, Zhejiang, People's Republic of China.
Zitieren
APA
Xuan, F., Ding, M., Qiu, Z., Wang, L., & Xu, H. (2026). Cost-Effectiveness of Culmerciclib Plus Fulvestrant for Previously Treated HR-Positive/HER2-Negative Advanced Breast Cancer in China: An Integrated GBD 2023 Analysis. International Journal of Women's Health, Volume 18, 1-18. https://doi.org/10.2147/ijwh.s636398
Vancouver
Xuan F, Ding M, Qiu Z, Wang L, Xu H. Cost-Effectiveness of Culmerciclib Plus Fulvestrant for Previously Treated HR-Positive/HER2-Negative Advanced Breast Cancer in China: An Integrated GBD 2023 Analysis. International Journal of Women's Health. 2026;Volume 18:1-18. doi:10.2147/ijwh.s636398
BibTeX
@article{Xuan2026,
author = {Xuan, Feng and Ding, Mengjuan and Qiu, Zhaoqi and Wang, Liejiong and Xu, Haiyan},
title = {Cost-Effectiveness of Culmerciclib Plus Fulvestrant for Previously Treated HR-Positive/HER2-Negative Advanced Breast Cancer in China: An Integrated GBD 2023 Analysis},
journal = {International Journal of Women's Health},
year = {2026},
volume = {Volume 18},
pages = {1--18},
doi = {10.2147/ijwh.s636398}
}
EUVIMED